- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
Patent holdings for IPC class A61K 31/542
Total number of patents in this class: 427
10-year publication summary
|
43
|
44
|
39
|
30
|
24
|
32
|
39
|
21
|
29
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Eisai R&D Management Co., Ltd. | 1270 |
17 |
| Eli Lilly and Company | 3733 |
16 |
| Shionogi & Co., Ltd. | 886 |
11 |
| Sentiss Pharma Private Limited | 25 |
10 |
| F. Hoffmann-La Roche AG | 7951 |
9 |
| Pfizer Inc. | 3365 |
8 |
| Erasca, Inc. | 84 |
8 |
| Genentech, Inc. | 3878 |
7 |
| Takeda Pharmaceutical Company Limited | 2945 |
7 |
| Alcon, Inc. | 5199 |
6 |
| Newave Pharmaceutical Inc. | 60 |
6 |
| Novartis AG | 11254 |
5 |
| Hoffmann-La Roche Inc. | 3280 |
5 |
| Janssen Pharmaceutica N.V. | 3610 |
5 |
| Wockhardt Limited | 229 |
5 |
| Graybug Vision, Inc. | 27 |
5 |
| Glaxosmithkline Intellectual Property Development Limited | 738 |
4 |
| Santen Pharmaceutical Co., Ltd. | 625 |
4 |
| Bristol-myers Squibb Company | 4861 |
3 |
| Janssen Pharmaceuticals, Inc. | 411 |
3 |
| Other owners | 283 |